• In May 2026, Freeport-McMoRan Inc. and its subsidiary PT Freeport Indonesia entered into a new five-year, US$3,000 million senior unsecured revolving credit facility, replacing the prior 2022 agreement while maintaining key features such as the US$500 million subsidiary borrowing cap, US$1,500 million letter-of-credit sublimit, and a total leverage ratio covenant of 3.75 to 1.00.
• This refreshed facility, which was put in place with no outstanding borrowings and only about US$5 million of letters of credit rolled over, reinforces the company’s liquidity backstop and financial flexibility without materially changing its existing debt structure or subsidiary exposure.
• We’ll now examine how this refreshed US$3,000 million revolving credit facility, and its leverage covenants, interacts with Freeport-McMoRan’s investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Freeport-McMoRan Investment Narrative Recap

To own Freeport-McMoRan, you need to believe copper remains central to electrification while the company manages its heavy Indonesian exposure and regulatory complexity. Right now, the key catalyst is higher copper-linked cash generation, and the biggest risk is policy and contract uncertainty around Grasberg and Indonesia. The new US$3,000 million credit facility does not materially change that equation, but it does modestly strengthen Freeport’s short term liquidity and flexibility around those same risks.

Among recent announcements, the February 2026 memorandum of understanding with the Indonesian government on a life of resource extension at Grasberg is most relevant. It sits directly alongside the new credit facility: one frames how long key Indonesian assets might run, while the other shores up balance sheet capacity if approvals, regulations, or operating conditions around that extension become more challenging than expected.

Yet even with stronger liquidity, investors should be aware that Indonesian policy shifts around Grasberg could still...

Freeport-McMoRan's narrative projects $36.4 billion revenue and $5.7 billion earnings by 2029. This requires 11.3% yearly revenue growth and a $3.0 billion earnings increase from $2.7 billion today.

Uncover how Freeport-McMoRan's forecasts yield a $67.95 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Compared with consensus, the most pessimistic analysts were already assuming only about US$34.0 billion of revenue and US$3.3 billion of earnings by 2029, so if you worry about resource nationalism and regulatory pressure, this new facility might or might not soften that downside story as views are updated.

Explore 5 other fair value estimates on Freeport-McMoRan - why the stock might be worth as much as 35% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Freeport-McMoRan research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Freeport-McMoRan research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Freeport-McMoRan's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.